Janus Henderson Group PLC Increases Stock Holdings in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY)

Janus Henderson Group PLC increased its holdings in shares of Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) by 31.2% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 221,063 shares of the company’s stock after buying an additional 52,563 shares during the period. Janus Henderson Group PLC owned about 0.39% of Harmony Biosciences worth $7,607,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also recently made changes to their positions in HRMY. Deep Track Capital LP purchased a new position in shares of Harmony Biosciences during the 4th quarter valued at approximately $49,894,000. Vanguard Group Inc. lifted its position in shares of Harmony Biosciences by 36.4% during the 4th quarter. Vanguard Group Inc. now owns 4,733,609 shares of the company’s stock valued at $162,883,000 after buying an additional 1,262,362 shares in the last quarter. Marshall Wace LLP lifted its position in shares of Harmony Biosciences by 165.2% during the 4th quarter. Marshall Wace LLP now owns 929,744 shares of the company’s stock valued at $31,992,000 after buying an additional 579,103 shares in the last quarter. Norges Bank purchased a new position in shares of Harmony Biosciences during the 4th quarter valued at approximately $16,118,000. Finally, Pacer Advisors Inc. lifted its position in shares of Harmony Biosciences by 18.2% during the 4th quarter. Pacer Advisors Inc. now owns 2,279,918 shares of the company’s stock valued at $78,452,000 after buying an additional 351,582 shares in the last quarter. Hedge funds and other institutional investors own 86.23% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on HRMY shares. Mizuho increased their target price on Harmony Biosciences from $44.00 to $48.00 and gave the company an “outperform” rating in a research report on Thursday. Needham & Company LLC restated a “buy” rating and issued a $49.00 price objective on shares of Harmony Biosciences in a report on Tuesday, May 6th. Cantor Fitzgerald upgraded Harmony Biosciences to a “strong-buy” rating in a report on Tuesday, May 13th. Deutsche Bank Aktiengesellschaft began coverage on Harmony Biosciences in a report on Tuesday, February 11th. They issued a “buy” rating and a $55.00 price objective on the stock. Finally, HC Wainwright restated a “buy” rating and issued a $70.00 price objective on shares of Harmony Biosciences in a report on Tuesday, April 8th. Eight research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus price target of $52.78.

Harmony Biosciences Stock Up 2.5%

Shares of HRMY opened at $35.07 on Friday. Harmony Biosciences Holdings, Inc. has a 52-week low of $26.47 and a 52-week high of $41.61. The company has a market capitalization of $2.01 billion, a PE ratio of 16.62, a price-to-earnings-growth ratio of 0.47 and a beta of 0.82. The stock has a fifty day simple moving average of $31.45 and a two-hundred day simple moving average of $33.96. The company has a quick ratio of 3.20, a current ratio of 3.24 and a debt-to-equity ratio of 0.28.

Harmony Biosciences (NASDAQ:HRMY) last issued its earnings results on Tuesday, May 6th. The company reported $0.78 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.59 by $0.19. Harmony Biosciences had a return on equity of 23.16% and a net margin of 17.98%. The business had revenue of $184.73 million during the quarter, compared to the consensus estimate of $184.26 million. During the same period last year, the company earned $0.67 EPS. The company’s revenue for the quarter was up 19.5% on a year-over-year basis. As a group, equities analysts forecast that Harmony Biosciences Holdings, Inc. will post 2.43 EPS for the current year.

Harmony Biosciences Profile

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.